ArticleEClinicalMedicine2026
Efficacy and safety of temporary selective portal vein embolization before major hepatectomy (EMBORES): a phase 2 trial.
Article in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02945059 (Multicentric Prospective Study Assessing the Efficiency of Preoperative Reversible Selective Portal Vein Embolization in Patients Requiring Major Hepatic Resection), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multicentric Prospective Study Assessing the Efficiency of Preoperative Reversible Selective Portal Vein Embolization in Patients Requiring Major Hepatic Resection
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Portal vein embolization (PVE) is routinely used before major hepatectomy to induce hypertrophy of the future liver remnant (FLR) and reduce post-hepatectomy liver failure. Conventional PVE relies on permanent embolic agents, resulting in irreversible portal occlusion, which may be associated with complications and may limit subsequent therapeutic options in patients who do not ultimately undergo resection. Whether transient portal deprivation alone can induce clinically relevant liver regeneration remains unknown. We evaluated the efficacy and safety of temporary selective PVE using an absorbable gelatin agent. Methods: EMBORES was a multicenter prospective single-arm phase II trial conducted in six French hepatobiliary centers. Between May 3, 2018, and May 3, 2021, adult patients requiring major hepatectomy and preoperative PVE were included. Selective portal branches were embolized using powdered absorbable gelatin sponge. The primary endpoint was FLR hypertrophy assessed by computed tomography (CT) volumetry 4-6 weeks after PVE. Secondary endpoints included feasibility, morbidity, portal vein recanalization, and surgical outcomes. This trial is registered with ClinicalTrials.gov, NCT02945059. Findings: 34 patients were enrolled and 32 underwent temporary PVE. Mean age was 63.4 years (standard deviation [SD] 8.9), and colorectal liver metastases accounted for 18 (56%) of 32 indications. Technical success was achieved in all patients. One major complication occurred (1 [3.1%] of 32 patients), while liver function remained preserved. Complete and partial portal vein recanalization were observed in 17 (53%) and 9 (28%) of 32 patients, respectively. Mean FLR volume increased from 580 (SD 169) mL to 690 (SD 188) mL, corresponding to a mean hypertrophy ratio of 9.5% (SD 10.2). Five patients required repeat embolization using a permanent agent because of insufficient hypertrophy. Overall, 23 (71.8%) of 32 patients underwent major hepatectomy, with no postoperative mortality. Interpretation: Temporary PVE using an absorbable embolic agent is feasible, safe, and capable of inducing clinically meaningful liver hypertrophy before major hepatectomy, supporting the concept that transient portal vein occlusion may be sufficient to stimulate liver regeneration in selected patients. Funding: The EMBORES study was funded by the French Ministry of Health through a national hospital clinical research program grant awarded in 2015 (Programme Hospitalier de Recherche Clinique National, PHRC-15-15-0201).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.